Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, BTIG Research Analyst Says

Alto Neuroscience (NYSE:ANRO) had its price objective upped by investment analysts at BTIG Research from $28.00 to $37.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target indicates a potential upside of 27.06% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research report on Wednesday, June 17th. Wedbush raised their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Alto Neuroscience from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.38.

Alto Neuroscience Stock Up 1.2%

ANRO opened at $29.12 on Thursday. Alto Neuroscience has a 12 month low of $3.02 and a 12 month high of $29.70. The company has a market cap of $1.02 billion, a PE ratio of -12.03 and a beta of 1.06. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average of $25.44 and a 200 day moving average of $22.57.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. On average, sell-side analysts expect that Alto Neuroscience will post -3.14 EPS for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Several hedge funds have recently added to or reduced their stakes in ANRO. Bank of New York Mellon Corp purchased a new position in shares of Alto Neuroscience in the 2nd quarter worth about $2,014,000. GK Wealth Management LLC purchased a new position in shares of Alto Neuroscience during the 2nd quarter valued at about $226,000. Perceptive Advisors LLC raised its holdings in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after buying an additional 225,500 shares in the last quarter. Bank of America Corp DE lifted its position in Alto Neuroscience by 131.5% in the 1st quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock worth $577,000 after buying an additional 14,585 shares during the last quarter. Finally, Eversept Partners LP bought a new stake in Alto Neuroscience in the 1st quarter worth approximately $2,814,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.